BMY Q1 2026 Earnings Analysis

Absolutely, Alex. But before we get started, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

The numbers tell a solid story, Alex. Total revenue came in at $11.5 billion, up 1% year-over-year. But here's what's really interesting - their growth portfolio, which includes their newer, more innovative drugs, grew 9% to $6.2 billion. That's nearly half their total revenue now coming from these growth assets.

Several winners here. Reblozyl grew 15%, Breyanzi - their CAR-T cell therapy - jumped 53%, and Camzyos nearly doubled to $314 million. But the elephant in the room is still Eliquis, their blood thinner, which brought in $4.1 billion and grew 13% despite facing generic competition eventually.

Yes, this is crucial, Alex. They have what Boerner called an "increasing cadence of pivotal readouts" coming in late 2026. We're talking about Milvexian for atrial fibrillation and stroke prevention, Cobenfy for Alzheimer's psychosis, and some important cancer drug data. These aren't just incremental updates - these could define the company's growth trajectory for years.

Potentially massive, Alex. They're testing it against Eliquis - their own blockbuster drug - trying to show it's just as effective but causes less bleeding. Think about it: if you can reduce the main side effect that keeps doctors from prescribing blood thinners, you could expand the treatable patient population significantly. Adam Lenkowsky, their Chief Commercialization Officer, called it having "true blockbuster potential."

Right, and this addresses a huge unmet need. Current antipsychotics used in elderly dementia patients carry black box warnings and cause serious side effects like movement disorders and cognitive impairment. Cobenfy works on a completely different mechanism - muscarinic receptors instead of dopamine. If it works, it could be the first approved treatment specifically for Alzheimer's psychosis.

What struck me was how specific they were about the Milvexian trial design. They disclosed that they're testing for non-inferiority to Eliquis with specific margins, then looking for superiority on bleeding reduction. That level of detail suggests real confidence in their approach. They recruited 20,500 patients - that's a massive study.

The financial discipline story is important here, Alex. They're in the middle of a $2 billion cost-savings initiative running through 2027, which is giving them flexibility to invest in R&D and potential acquisitions. Boerner mentioned they're "size agnostic" when it comes to business development - they have the financial firepower for deals of various sizes.

That's huge if they can deliver on it, Alex. Drug development is notoriously slow and expensive. They mentioned partnerships with companies like Ferro to design trials more efficiently. In an industry where getting drugs to market faster can mean billions in additional revenue, these productivity gains could be a real competitive advantage.

This is their attempt to build the next generation of treatments for multiple myeloma after their older drugs face generic competition. These are oral medications that could potentially replace current standards of care. Boerner seemed particularly excited about this platform, mentioning they have additional degraders in development beyond just these two drugs.

The back half of 2026 is absolutely critical. We'll get data on Milvexian, Cobenfy, several cancer drugs, and more. Success in even a couple of these programs could validate their R&D strategy and support long-term growth. Failure could mean they need to rely more heavily on business development to fill gaps.

The main risk is execution. They have a lot of balls in the air, and pharmaceutical development is inherently risky. They're also facing competition in several key areas - Camzyos now has a competitor, and the blood thinner market is getting more crowded. But they seem to have the financial resources and strategic focus to navigate these challenges.

Just remember that everything we've discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.

Thanks everyone, and remember to always do your own research before making any investment decisions. --- *Total word count: approximately 1,150 words* *Estimated runtime: 6-7 minutes*